5.80
-0.05(-0.85%)
Currency In EUR
Sector
Healthcare
Industry
Medical - Care Facilities
Employees
783
First IPO Date
March 27, 2007
| Name | Title | Pay | Year Born |
| Jakub Julian Baran | Chairman of the Management Board & Chief Executive Officer | 436,973 | N/A |
| Thomas Pfaadt | Chief Financial Officer & Member of Management Board | 168,409 | N/A |
| Tomasz Franciszek Baran | Vice President of the Management Board & CMO | 307,755 | N/A |
| Conelia Wittke-Kothe | CCO & Member of Management Board | 0 | N/A |
| Santiago Luengo | Managing Director of Secuvita | 0 | N/A |
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.